Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617

Mostrar otras versiones (1)

COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused over 5 million deaths to date. Although multiple vaccines are available, breakthrough infections occur especially by emerging variants. Effective therapeutic options such as monoclonal antibodies (mAbs) are still critical. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Lei, Hu, Yingxia, Mankowski, Madeleine C., Ren, Ping, Chen, Rita E., Wei, Jin, Zhao, Min, Li, Tongqing, Tripler, Therese, Ye, Lupeng, Chow, Ryan D., Fang, Zhenhao, Wu, Chunxiang, Dong, Matthew B., Cook, Matthew, Wang, Guilin, Clark, Paul, Nelson, Bryce, Klein, Daryl, Sutton, Richard, Diamond, Michael S., Wilen, Craig B., Xiong, Yong, Chen, Sidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722602/
https://www.ncbi.nlm.nih.gov/pubmed/34981065
http://dx.doi.org/10.1101/2021.12.21.473733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722602/
https://www.ncbi.nlm.nih.gov/pubmed/34981065
http://dx.doi.org/10.1101/2021.12.21.473733

Ejemplares similares